Pfizer (NYSE:PFE) Receives Neutral Rating from The Goldman Sachs Group

Pfizer (NYSE:PFE - Get Free Report)'s stock had its "neutral" rating restated by stock analysts at The Goldman Sachs Group in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. They currently have a $25.00 target price on the biopharmaceutical company's stock, down from their prior target price of $32.00. The Goldman Sachs Group's price objective points to a potential upside of 14.22% from the company's current price.

A number of other research analysts have also weighed in on the stock. UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Bank of America reaffirmed a "neutral" rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of "Moderate Buy" and an average price target of $31.07.

Remove Ads

Pfizer Stock Up 1.4 %

Pfizer stock traded up $0.30 during midday trading on Tuesday, reaching $21.89. The stock had a trading volume of 55,013,451 shares, compared to its average volume of 40,243,601. The company has a fifty day moving average price of $25.25 and a two-hundred day moving average price of $26.40. Pfizer has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $124.14 billion, a P/E ratio of 15.52, a PEG ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the previous year, the company posted $0.10 earnings per share. The company's quarterly revenue was up 24.7% on a year-over-year basis. As a group, equities analysts expect that Pfizer will post 2.95 EPS for the current fiscal year.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.06% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Retirement Wealth Solutions LLC bought a new position in Pfizer during the fourth quarter worth about $26,000. Rialto Wealth Management LLC purchased a new position in Pfizer during the 4th quarter valued at about $26,000. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer in the fourth quarter worth about $27,000. Gould Capital LLC boosted its position in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares during the period. Finally, Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer during the fourth quarter valued at approximately $28,000. Institutional investors own 68.36% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.